Atrial fibrillation risk factors: Difference between revisions

Jump to navigation Jump to search
Line 41: Line 41:


===Irreversible Underlying Conditions Associated with Atrial Fibrillation===
===Irreversible Underlying Conditions Associated with Atrial Fibrillation===
*[[Hypertrophic Obstructive Cardiomyopathy]]
*[[Hypertrophic Obstructive Cardiomyopathy]] <ref name="pmid11156892">{{cite journal| author=Allessie MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ | display-authors=etal| title=Pathophysiology and prevention of atrial fibrillation. | journal=Circulation | year= 2001 | volume= 103 | issue= 5 | pages= 769-77 | pmid=11156892 | doi=10.1161/01.cir.103.5.769 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11156892  }} </ref>
*[[Heart failure]]<ref name="pmid21920917">{{cite journal| author=Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL| title=Atrial fibrillation and mortality in heart failure: a community study. | journal=Circ Heart Fail | year= 2011 | volume= 4 | issue= 6 | pages= 740-6 | pmid=21920917 | doi=10.1161/CIRCHEARTFAILURE.111.962688 | pmc=3222889 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21920917  }} </ref>
*[[Heart failure]]<ref name="pmid21920917">{{cite journal| author=Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL| title=Atrial fibrillation and mortality in heart failure: a community study. | journal=Circ Heart Fail | year= 2011 | volume= 4 | issue= 6 | pages= 740-6 | pmid=21920917 | doi=10.1161/CIRCHEARTFAILURE.111.962688 | pmc=3222889 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21920917  }} </ref>
*[[Short QT syndrome]]
*[[Short QT syndrome]]

Revision as of 18:57, 19 August 2021



Resident
Survival
Guide


Sinus rhythm
Atrial fibrillation

Atrial Fibrillation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atrial Fibrillation from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Special Groups

Postoperative AF
Acute Myocardial Infarction
Wolff-Parkinson-White Preexcitation Syndrome
Hypertrophic Cardiomyopathy
Hyperthyroidism
Pulmonary Diseases
Pregnancy
ACS and/or PCI or valve intervention
Heart failure

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

EKG Examples
A-Fib with LBBB

Chest X Ray

Echocardiography

Holter Monitoring and Exercise Stress Testing

Cardiac MRI

Treatment

Rate and Rhythm Control

Cardioversion

Overview
Electrical Cardioversion
Pharmacological Cardioversion

Anticoagulation

Overview
Warfarin
Converting from or to Warfarin
Converting from or to Parenteral Anticoagulants
Dabigatran

Maintenance of Sinus Rhythm

Surgery

Catheter Ablation
AV Nodal Ablation
Surgical Ablation
Cardiac Surgery

Specific Patient Groups

Primary Prevention

Secondary Prevention

Supportive Trial Data

Cost-Effectiveness of Therapy

Case Studies

Case #1

Atrial fibrillation risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atrial fibrillation risk factors

CDC on Atrial fibrillation risk factors

Atrial fibrillation risk factors in the news

Blogs on Atrial fibrillation risk factors

Directions to Hospitals Treating Atrial fibrillation risk factors

Risk calculators and risk factors for Atrial fibrillation risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]

Overview

Atrial fibrillation (AF) affects millions of people, and the number increases with increasing age. Men are more likely than women to have the condition. In the United States, AF is more common among Caucasians than African-Americans or Hispanic Americans. The risk of AF increases with age. This is mostly because the risk for heart disease and other conditions that can cause AF also increases with increasing age.

Risk Factors

Reversible or Modifiable Underlying Conditions Associated with Atrial Fibrillation

Irreversible Underlying Conditions Associated with Atrial Fibrillation

Risk Stratification

  • Once a patient develops atrial fibrillation, their risk of subsequent events can be assessed using the following scores:
  • The risk of bleeding associated with anticoagulation can be assessed using the following score:

Risk factors for Ischemic Stroke or Systemic Embolization in Patients with Non-valvular Atrial Fibrillation

Risk factors and relative risks are tabulated below: [6][7][3]

Risk Factor Relative Risk
Advanced age (continuous, per decade)
1.4
History of hypertension
1.6
Heart failure or impaired left ventricular systolic function
1.4
Coronary artery disease (CAD)
1.5
Diabetes mellitus (DM)
1.7
Previous stroke or Transient Ischemic Attack (TIA)
2.5

Other Risk Factors

Reference

  1. Ridker PM, Gibson CM, Lopez R (1989). "Atrial fibrillation induced by breath spray". N Engl J Med. 320 (2): 124. PMID 2914028.
  2. May Khan A, Lubitz SA, Sullivan LM, Sun JX, Levy D, Vasan RS; et al. (2012). "Low Serum Magnesium and the Development of Atrial Fibrillation in the Community: The Framingham Heart Study". Circulation. doi:10.1161/CIRCULATIONAHA.111.082511. PMID 23172839.
  3. 3.0 3.1 3.2 3.3 Allessie MA, Boyden PA, Camm AJ, Kléber AG, Lab MJ, Legato MJ; et al. (2001). "Pathophysiology and prevention of atrial fibrillation". Circulation. 103 (5): 769–77. doi:10.1161/01.cir.103.5.769. PMID 11156892.
  4. Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL (2011). "Atrial fibrillation and mortality in heart failure: a community study". Circ Heart Fail. 4 (6): 740–6. doi:10.1161/CIRCHEARTFAILURE.111.962688. PMC 3222889. PMID 21920917.
  5. McManus DD, Rienstra M, Benjamin EJ (2012). "An update on the prognosis of patients with atrial fibrillation". Circulation. 126 (10): e143–6. doi:10.1161/CIRCULATIONAHA.112.129759. PMC 3678907. PMID 22949543.
  6. Estes NA, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS et al. (2008) ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation 117 (8):1101-20. DOI:10.1161/CIRCULATIONAHA.107.187192 PMID: 18283199
  7. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M; et al. (2008). "Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation". Eur Heart J. 29 (9): 1181–9. doi:10.1093/eurheartj/ehn139. PMID 18397874.

Template:WH Template:WS CME Category::Cardiology